… observed with gemcitabine in this study is similar to that seen in phase II studies in other
solid tumors, including ovarian" and breast cancer.'" However, phase I studies have shown that …

… To assure the safety and to provide effective care for patients with untreated extensive-stage
SCLC, we used a “windowed” Phase II study design, with frequent evaluations to allow …

… activity in animal studies. Purpose: Our randomized phase II study was designed to … agents
in the treatment of stage IV metastatic non-small-cell lung cancer. Methods: Eligible patients (…

… mg/m2 early in this study was based largely on the toxicity … phase II study of colorectal cancer
that is using the same dose and schedule. The toxicity seen in all other phase II trials of lung…

… Purpose: Mammalian target of rapamycin (mTOR) is a promising target in small cell lung
cancer (SCLC). We designed a phase II study of everolimus, an mTOR inhibitor, in previously …

… We did a phase II study of single-agent erlotinib as first-line therapy in patients with advanced
NSCLC. We also did biological studies on tumor samples of patients entered in the study …

… However, non-small cell lung cancer (NSCLC) frequently occurs in people with an extensive
… In 1998, we initiated a phase II study using SBRT for stage I NSCLC. The aim of this study …

… In our phase II study, gemcitabine was administered weekly, three times over 28 days.
Cisplatin was given on day 2 of each cycle to maintain the synergistic effect by close …

… We conducted a phase II study of dasatinib as first-line treatment for metastatic NSCLC. The
primary objective of this trial was to determine the rate of progression-free survival (PFS) at …

… and is upregulated in the majority of small cell lung cancers (SCLC). Navitoclax, or … -2,
resulting in single-agent activity in preclinical SCLC models. This article describes the first phase II …